Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis

In COVID-19-related acute respiratory distress syndrome (ARDS), the clot play a role in gas exchange abnormalities. Fibrinolytic therapy can improve alveolar ventilation by restoring blood flow. In this systematic review and meta-analysis protocol, we aim to assess the safety and efficacy of fibrino...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2023-01, Vol.13 (1), p.e066623-e066623
Main Authors: Savioli, Felicio, Ribeiro Dos Santos, Lucas, Duarte, Marcio Luis, Feitosa do Carmo, Andreia Cristina, Gois, Aecio, Nakano, Luis, Da Silva Ramos, Fernando Jose, Pastore, Laerte, Costa, Eduardo Leite Vieira
Format: Article
Language:English
Subjects:
Clinical trials
Coronaviruses
COVID-19
Handbooks
Heart attacks
Hemorrhage
Humans
Intensive Care
Intervention
Length of stay
Meta-analysis
Meta-Analysis as Topic
Patients
Pneumonia
Respiratory distress syndrome
Respiratory Distress Syndrome - drug therapy
Sepsis
Systematic review
Systematic Reviews as Topic
Thrombolytic Therapy
Ventilators
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In COVID-19-related acute respiratory distress syndrome (ARDS), the clot play a role in gas exchange abnormalities. Fibrinolytic therapy can improve alveolar ventilation by restoring blood flow. In this systematic review and meta-analysis protocol, we aim to assess the safety and efficacy of fibrinolytic therapy in such a population. We will perform a systematic search in MEDLINE, EMBASE, Cochrane CENTRAL and LILACS databases without language restrictions for relevant randomised controlled trials (RCTs) and quasi-RCTs. Two review authors will independently perform data extraction and quality assessments of data from included studies. In case of divergence, a third author will be contacted. The Cochrane handbook will be used for guidance. If the results are not appropriate for a meta-analysis, a descriptive analysis will be performed. This systematic review and meta-analysis protocol will provide current evidence about the safety and efficacy of fibrinolytic therapy in patients with COVID-19 and ARDS. These findings will provide if fibrinolytic therapy might be an option for a desperate clinical setting, where all medical efforts have been used. PROSPERO CRD42020187482. Ethics committee approval is not necessary. We intend to update the public registry, report any protocol amendments and publish the results in a widely accessible journal.
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2022-066623